메뉴 건너뛰기




Volumn 3, Issue 4, 2011, Pages 362-373

Urothelial carcinomas: A focus on human epidermal receptors signaling

Author keywords

Bladder cancer; EGFR; HER2; Human epidermal receptors; Trastuzumab; Urothelial carcinoma

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ETOPOSIDE; GEFITINIB;

EID: 80051743870     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (40)

References (95)
  • 3
    • 0027297154 scopus 로고
    • A phase II study of methotrexate, vinblastine, doxorubi-cin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma
    • Moore MJ, Iscoe N, Tannock IF.A phase II study of methotrexate, vinblastine, doxorubi-cin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150(4): 1131-1134.
    • (1993) J Urol , vol.150 , Issue.4 , pp. 1131-1134
    • Moore, M.J.1    Iscoe, N.2    Tannock, I.F.3
  • 4
    • 29144519778 scopus 로고    scopus 로고
    • Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: Long-term follow-up of a 3-week regimen
    • Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, Adamo B, Rossello R, Scandurra G, Scimone A. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69(5): 391-398.
    • (2005) Oncology , vol.69 , Issue.5 , pp. 391-398
    • Adamo, V.1    Magno, C.2    Spitaleri, G.3    Garipoli, C.4    Maisano, C.5    Alafaci, E.6    Adamo, B.7    Rossello, R.8    Scandurra, G.9    Scimone, A.10
  • 6
    • 0032858246 scopus 로고    scopus 로고
    • Gem-citabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clini-cal Trials Group
    • Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L. Gem-citabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clini-cal Trials Group. J Clin Oncol 1999; 17(9): 2876-2881.
    • (1999) J Clin Oncol , vol.17 , Issue.9 , pp. 2876-2881
    • Moore, M.J.1    Winquist, E.W.2    Murray, N.3    Tannock, I.F.4    Huan, S.5    Bennett, K.6    Walsh, W.7    Seymour, L.8
  • 9
    • 36549023828 scopus 로고    scopus 로고
    • Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study (abstract #LBA 5030)
    • Bellmunt J, von der Maase H, Mead GM, Heyer J, Houede N, Paz-Ares LG, Winquist E, Lauf-man LR, de Wit R, Sylvester R. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study (abstract #LBA 5030). J Clin Oncol 2007; 25: 965s.
    • (2007) J Clin Oncol , vol.965 s , pp. 25
    • Bellmunt, J.1    von der Maase, H.2    Mead, G.M.3    Heyer, J.4    Houede, N.5    Paz-Ares, L.G.6    Winquist, E.7    Lauf-Man, L.R.8    de Wit, R.9    Sylvester, R.10
  • 10
    • 1542329005 scopus 로고    scopus 로고
    • The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal anti-bodies and tyrosine kinase inhibitors
    • Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal anti-bodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-457.
    • (2004) Annu Rev Med , vol.55 , pp. 433-457
    • Rowinsky, E.K.1
  • 11
    • 0034730323 scopus 로고    scopus 로고
    • Receptor tyrosine kinases: Specific outcomes from general signals
    • Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell 2000; 103: 13-15.
    • (2000) Cell , vol.103 , pp. 13-15
    • Simon, M.A.1
  • 12
    • 0031827950 scopus 로고    scopus 로고
    • The erbB/HER type1 tyrosine kinase receptor family
    • Walker RA. The erbB/HER type1 tyrosine kinase receptor family. J Pathol 1998; 185: 234-35.
    • (1998) J Pathol , vol.185 , pp. 234-235
    • Walker, R.A.1
  • 13
    • 0034644539 scopus 로고    scopus 로고
    • Cell signaling by receptor tyro-sine kinases
    • Schlessinger J. Cell signaling by receptor tyro-sine kinases. Cell 2000; 103: 211-225.
    • (2000) Cell , vol.103 , pp. 211-225
    • Schlessinger, J.1
  • 14
    • 0032791110 scopus 로고    scopus 로고
    • Take your partners, please: Signal diversification by the erbB family of receptor tyrosine kinases
    • Daly RJ. Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 1999; 16: 255-263.
    • (1999) Growth Factors , vol.16 , pp. 255-263
    • Daly, R.J.1
  • 15
    • 55849126233 scopus 로고    scopus 로고
    • Signal integration: A framework for understanding the efficacy of therapeutics targeting the hu- man EGFR family
    • Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the hu- man EGFR family J Clin Invest 2008; 118(11): 3574-3581.
    • (2008) J Clin Invest , vol.118 , Issue.11 , pp. 3574-3581
    • Shepard, H.M.1    Brdlik, C.M.2    Schreiber, H.3
  • 17
    • 0024355092 scopus 로고
    • Autocrine interaction between TGF-a and the EGF - re-ceptor: Quantitative requirements for induc-tion of the malignant phenotype
    • Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, Di Fiore PP. Autocrine interaction between TGF-a and the EGF - re-ceptor: quantitative requirements for induc-tion of the malignant phenotype. Oncogene 1989; 4: 831-838.
    • (1989) Oncogene , vol.4 , pp. 831-838
    • di Marco, E.1    Pierce, J.H.2    Fleming, T.P.3    Kraus, M.H.4    Molloy, C.J.5    Aaronson, S.A.6    di Fiore, P.P.7
  • 18
    • 44149087535 scopus 로고    scopus 로고
    • ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    • Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 215-223.
    • (2008) J Mammary Gland Biol Neoplasia , vol.13 , pp. 215-223
    • Stern, D.F.1
  • 19
    • 33744912774 scopus 로고    scopus 로고
    • Controlled activation of ErbB1/ErbB2 heterodimers pro-mote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: Implications for progression of ErbB2-overexpressing tumors
    • Zhan L, Xiang B, Muthuswamy SK. Controlled activation of ErbB1/ErbB2 heterodimers pro-mote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res 2006; 66: 5201-5208.
    • (2006) Cancer Res , vol.66 , pp. 5201-5208
    • Zhan, L.1    Xiang, B.2    Muthuswamy, S.K.3
  • 20
    • 49649103585 scopus 로고    scopus 로고
    • The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation
    • Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008; 283(26): 18393-18401.
    • (2008) J Biol Chem , vol.283 , Issue.26 , pp. 18393-18401
    • Najy, A.J.1    Day, K.C.2    Day, M.L.3
  • 21
    • 34247863773 scopus 로고    scopus 로고
    • The neuregulin-I/ErbB signaling system in development and disease
    • Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007; 190: 1-65.
    • (2007) Adv Anat Embryol Cell Biol , vol.190 , pp. 1-65
    • Britsch, S.1
  • 23
    • 37849046940 scopus 로고    scopus 로고
    • ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
    • Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
    • (2008) Ann Oncol , vol.19 , pp. 73-80
    • Revillion, F.1    Lhotellier, V.2    Hornez, L.3    Bonneterre, J.4    Peyrat, J.P.5
  • 24
    • 0031452314 scopus 로고    scopus 로고
    • Clinicopa-thological significance of epidermal growth factor and its receptor in human pancreatic cancer
    • Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, Dong M, Tamura K. Clinicopa-thological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997; 17: 3841-3847.
    • (1997) Anticancer Res , vol.17 , pp. 3841-3847
    • Uegaki, K.1    Nio, Y.2    Inoue, Y.3    Minari, Y.4    Sato, Y.5    Song, M.M.6    Dong, M.7    Tamura, K.8
  • 27
    • 7144227965 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
    • Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1997-1206.
    • (1997) Ann Oncol , vol.8 , pp. 1997-1206
    • Voldborg, B.R.1    Damstrup, L.2    Spang-Thomsen, M.3    Poulsen, H.S.4
  • 28
    • 0032731892 scopus 로고    scopus 로고
    • Tumor invasion: Role of growth factor - induced cell motility
    • Wells A. Tumor invasion: role of growth factor - induced cell motility. Adv Cancer Res 2000; 78: 31-101.
    • (2000) Adv Cancer Res , vol.78 , pp. 31-101
    • Wells, A.1
  • 29
    • 0032549570 scopus 로고    scopus 로고
    • Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts
    • Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425: 145-150.
    • (1998) FEBS Lett , vol.425 , pp. 145-150
    • Verbeek, B.S.1    Adriaansen-Slot, S.S.2    Vroom, T.M.3    Beckers, T.4    Rijksen, G.5
  • 30
    • 0036651519 scopus 로고    scopus 로고
    • EGFR antisense treatment of human HNSCC cell lines down - regulates VEGF ex-pression and endothelial cell migration
    • Riedel F, Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down - regulates VEGF ex-pression and endothelial cell migration. Int J Oncol 2002; 21: 11-16.
    • (2002) Int J Oncol , vol.21 , pp. 11-16
    • Riedel, F.1    Gotte, K.2    Li, M.3    Hormann, K.4    Grandis, J.R.5
  • 31
    • 0033650082 scopus 로고    scopus 로고
    • Cell biology of lymphatics metasta-sis. The potential role of c-erbB oncogene signaling
    • Eccles SA. Cell biology of lymphatics metasta-sis. The potential role of c-erbB oncogene signaling. Recent Results Cancer Res 2000; 157: 41-54.
    • (2000) Recent Results Cancer Res , vol.157 , pp. 41-54
    • Eccles, S.A.1
  • 35
    • 84920241849 scopus 로고
    • Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tu-mours
    • Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tu-mours. Lancet 1985; 1: 366-368.
    • (1985) Lancet , vol.1 , pp. 366-368
    • Neal, D.E.1    Marsh, C.2    Bennett, M.K.3    Abel, P.D.4    Hall, R.R.5    Sainsbury, J.R.6    Harris, A.L.7
  • 36
    • 0025237455 scopus 로고
    • The epidermal growth factor receptor and the prognosis of bladder cancer
    • Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619-1625.
    • (1990) Cancer , vol.65 , pp. 1619-1625
    • Neal, D.E.1    Sharples, L.2    Smith, K.3    Fennelly, J.4    Hall, R.R.5    Harris, A.L.6
  • 37
    • 0025232322 scopus 로고
    • Clinical implications of the ex-pression of epidermal growth factor receptors in human transitional cell carcinoma
    • Messing EM. Clinical implications of the ex-pression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990; 50: 2530-2537.
    • (1990) Cancer Res , vol.50 , pp. 2530-2537
    • Messing, E.M.1
  • 39
    • 0028302276 scopus 로고
    • Expression of epi-dermal growth factor receptor in bladder can-cer as related to established prognostic fac-tors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
    • Lipponen P, Eskelinen M. Expression of epi-dermal growth factor receptor in bladder can-cer as related to established prognostic fac-tors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69: 1120-1125.
    • (1994) Br J Cancer , vol.69 , pp. 1120-1125
    • Lipponen, P.1    Eskelinen, M.2
  • 40
    • 34248365114 scopus 로고    scopus 로고
    • Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor recep-tor/ErbB1 expression in bladder cancer and their relation to clinical outcome
    • Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor recep-tor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007; 109: 2016-2024.
    • (2007) Cancer , vol.109 , pp. 2016-2024
    • Kramer, C.1    Klasmeyer, K.2    Bojar, H.3    Schulz, W.A.4    Ackermann, R.5    Grimm, M.O.6
  • 41
    • 0028939310 scopus 로고
    • Long-term outcome related to epidermal growth factor receptor status in bladder can-cer
    • Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder can-cer. J Urol 1995; 153: 919-925.
    • (1995) J Urol , vol.153 , pp. 919-925
    • Mellon, K.1    Wright, C.2    Kelly, P.3    Horne, C.H.4    Neal, D.E.5
  • 42
    • 33745272244 scopus 로고    scopus 로고
    • The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: A study in bladder cancer patients
    • Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 2006; 94: 1703-1709.
    • (2006) Br J Cancer , vol.94 , pp. 1703-1709
    • Memon, A.A.1    Sorensen, B.S.2    Meldgaard, P.3    Fokdal, L.4    Thykjaer, T.5    Nexo, E.6
  • 43
    • 38349061851 scopus 로고    scopus 로고
    • Growth factors and re-ceptors as prognostic markers in urothelial carcinoma
    • Black PC, Dinney CP. Growth factors and re-ceptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008; 9(1): 55-61.
    • (2008) Curr Urol Rep , vol.9 , Issue.1 , pp. 55-61
    • Black, P.C.1    Dinney, C.P.2
  • 45
    • 13244251056 scopus 로고    scopus 로고
    • Differential radio-sensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
    • Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. Differential radio-sensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 2005; 92: 125-130.
    • (2005) Br J Cancer , vol.92 , pp. 125-130
    • Maddineni, S.B.1    Sangar, V.K.2    Hendry, J.H.3    Margison, G.P.4    Clarke, N.W.5
  • 46
    • 33845476894 scopus 로고    scopus 로고
    • Inhibition of the epidermal growth factor re-ceptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly in-creases apoptosis
    • Munk M, Memon AA, Nexo E, Sorensen BS. Inhibition of the epidermal growth factor re-ceptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly in-creases apoptosis. BJU Int 2007; 99(1): 196-201.
    • (2007) BJU Int , vol.99 , Issue.1 , pp. 196-201
    • Munk, M.1    Memon, A.A.2    Nexo, E.3    Sorensen, B.S.4
  • 47
    • 67149143257 scopus 로고    scopus 로고
    • Dual epidermal growth factor receptor and vascular endothe-lial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner
    • Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothe-lial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009; 103(12): 1729-1737.
    • (2009) BJU Int , vol.103 , Issue.12 , pp. 1729-1737
    • Flaig, T.W.1    Su, L.J.2    McCoach, C.3    Li, Y.4    Raben, D.5    Varella-Garcia, M.6    Bemis, L.T.7
  • 48
    • 77957337150 scopus 로고    scopus 로고
    • VEGFR and EGFR inhibition increases epithelial cellular charac-teristics and chemotherapy sensitivity in mes-enchymal bladder cancer cells
    • Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular charac-teristics and chemotherapy sensitivity in mes-enchymal bladder cancer cells. Oncol Rep 2010; 24(4): 1019-1028.
    • (2010) Oncol Rep , vol.24 , Issue.4 , pp. 1019-1028
    • Li, Y.1    Yang, X.2    Su, L.J.3    Flaig, T.W.4
  • 49
  • 50
    • 70749137263 scopus 로고    scopus 로고
    • Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response
    • Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8: 94.
    • (2009) Mol Cancer , vol.8 , pp. 94
    • Bhuvaneswari, R.1    Gan, Y.Y.2    Soo, K.C.3    Olivo, M.4
  • 55
    • 0029655413 scopus 로고    scopus 로고
    • C-Erb-B2 in bladder cancer: Mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value
    • Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-Erb-B2 in bladder cancer: mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155(1): 321-326.
    • (1996) J Urol , vol.155 , Issue.1 , pp. 321-326
    • Mellon, J.K.1    Lunec, J.2    Wright, C.3    Horne, C.H.4    Kelly, P.5    Neal, D.E.6
  • 58
    • 0034782994 scopus 로고    scopus 로고
    • Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci-noma of the urinary bladder
    • Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci-noma of the urinary bladder. Clin Cancer Res 2001; 7: 1957-1962.
    • (2001) Clin Cancer Res , vol.7 , pp. 1957-1962
    • Chow, N.H.1    Chan, S.H.2    Tzai, T.S.3    Ho, C.L.4    Liu, H.S.5
  • 59
    • 0034890387 scopus 로고    scopus 로고
    • Her-2/neu overex-pression in muscle-invasive urothelial carci-noma of the bladder: Prognostic significance and comparative analysis in primary and me-tastatic tumors
    • Jimenez RE, Hussain M, Bianco FJ Jr, Vai-shampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ. Her-2/neu overex-pression in muscle-invasive urothelial carci-noma of the bladder: prognostic significance and comparative analysis in primary and me-tastatic tumors. Clin Cancer Res 2001; 7(8): 2440-2447.
    • (2001) Clin Cancer Res , vol.7 , Issue.8 , pp. 2440-2447
    • Jimenez, R.E.1    Hussain, M.2    Bianco Jr., F.J.3    Vai-Shampayan, U.4    Tabazcka, P.5    Sakr, W.A.6    Pontes, J.E.7    Wood Jr., D.P.8    Grignon, D.J.9
  • 60
    • 77951471947 scopus 로고    scopus 로고
    • Assessing Her-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients
    • Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing Her-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010; 21(4): 815-819.
    • (2010) Ann Oncol , vol.21 , Issue.4 , pp. 815-819
    • Laé, M.1    Couturier, J.2    Oudard, S.3    Radvanyi, F.4    Beuzeboc, P.5    Vieillefond, A.6
  • 61
    • 21044446131 scopus 로고    scopus 로고
    • Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based che-motherapy: A report from the Radiation Ther-apy Oncology Group
    • Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based che-motherapy: a report from the Radiation Ther-apy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62(2): 309-317.
    • (2005) Int J Radiat Oncol Biol Phys , vol.62 , Issue.2 , pp. 309-317
    • Chakravarti, A.1    Winter, K.2    Wu, C.L.3    Kaufman, D.4    Hammond, E.5    Parliament, M.6    Tester, W.7    Hagan, M.8    Grignon, D.9    Heney, N.10    Pollack, A.11    Sandler, H.12    Shipley, W.13
  • 62
    • 0026321254 scopus 로고
    • Use of inmunohisto-chemically demonstrated c-erb B-2 oncopro-tein expression as a prognostic factor in tran-sitional cell carcinoma of the urinary bladder
    • Lipponen P, Eskelinen M, Syrjänen S, Terva-hauta A, Syrjänen K. Use of inmunohisto-chemically demonstrated c-erb B-2 oncopro-tein expression as a prognostic factor in tran-sitional cell carcinoma of the urinary bladder. Eur Urol 1991; 20: 238-242.
    • (1991) Eur Urol , vol.20 , pp. 238-242
    • Lipponen, P.1    Eskelinen, M.2    Syrjänen, S.3    Terva-Hauta, A.4    Syrjänen, K.5
  • 64
    • 0032519575 scopus 로고    scopus 로고
    • Invasion of the bladder by transitional cell carcinoma: Its relation to his-tologic grade and expression of p53, MIB-1, c-Erb-B2, epidermal growth factor receptor and bcl-2
    • Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to his-tologic grade and expression of p53, MIB-1, c-Erb-B2, epidermal growth factor receptor and bcl-2. Cancer 1998; 82: 715-723
    • (1998) Cancer , vol.82 , pp. 715-723
    • Vollmer, R.T.1    Humphrey, P.A.2    Swanson, P.E.3    Wick, M.R.4    Hudson, M.L.5
  • 65
    • 0029655413 scopus 로고    scopus 로고
    • C-erbB-2 in bladder cancer: Mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value
    • Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155(1): 321-326.
    • (1996) J Urol , vol.155 , Issue.1 , pp. 321-326
    • Mellon, J.K.1    Lunec, J.2    Wright, C.3    Horne, C.H.4    Kelly, P.5    Neal, D.E.6
  • 67
    • 22344437801 scopus 로고    scopus 로고
    • ErbB receptor expression patterns in hu-man bladder cancer
    • Rajjayabun PH, Keegan PE, Lunec J, Mellon JK. ErbB receptor expression patterns in hu-man bladder cancer. Urology 2005; 66(1): 196-200.
    • (2005) Urology , vol.66 , Issue.1 , pp. 196-200
    • Rajjayabun, P.H.1    Keegan, P.E.2    Lunec, J.3    Mellon, J.K.4
  • 68
    • 33947720526 scopus 로고    scopus 로고
    • Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncopro-tein in the prognosis for the clinical course of bladder cancer
    • Masliukova EA, Pozharisski KM, Karelin MI, Startsev VIu, Ten VP. Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncopro-tein in the prognosis for the clinical course of bladder cancer. Vopr Onkol 2006; 52(6): 643-648.
    • (2006) Vopr Onkol , vol.52 , Issue.6 , pp. 643-648
    • Masliukova, E.A.1    Pozharisski, K.M.2    Karelin, M.I.3    Startsev, V.4    Ten, V.P.5
  • 69
    • 52649176386 scopus 로고    scopus 로고
    • Prognostic signifi-cance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
    • Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, Kumar R. Prognostic signifi-cance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008; 40(2): 321-327.
    • (2008) Int Urol Nephrol , vol.40 , Issue.2 , pp. 321-327
    • Kolla, S.B.1    Seth, A.2    Singh, M.K.3    Gupta, N.P.4    Hemal, A.K.5    Dogra, P.N.6    Kumar, R.7
  • 71
    • 35348900030 scopus 로고    scopus 로고
    • Does HER2 immu-noreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    • Tsai YS, Tzai TS, Chow NH. Does HER2 immu-noreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 2007; 79(3): 210-216.
    • (2007) Urol Int , vol.79 , Issue.3 , pp. 210-216
    • Tsai, Y.S.1    Tzai, T.S.2    Chow, N.H.3
  • 73
    • 77957135510 scopus 로고    scopus 로고
    • Human epi-dermal growth factor receptor 2 expression status provides independent prognostic infor-mation in patients with urothelial carcinoma of the urinary bladder
    • Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epi-dermal growth factor receptor 2 expression status provides independent prognostic infor-mation in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010; 106(8): 1216-1222.
    • (2010) BJU Int , vol.106 , Issue.8 , pp. 1216-1222
    • Bolenz, C.1    Shariat, S.F.2    Karakiewicz, P.I.3    Ashfaq, R.4    Ho, R.5    Sagalowsky, A.I.6    Lotan, Y.7
  • 75
    • 58549118062 scopus 로고    scopus 로고
    • No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
    • Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, Dodurga Y, Bagci H, Duzcan SE. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14(3): 261-266.
    • (2008) Pathol Oncol Res , vol.14 , Issue.3 , pp. 261-266
    • Caner, V.1    Turk, N.S.2    Duzcan, F.3    Tufan, N.L.4    Kelten, E.C.5    Zencir, S.6    Dodurga, Y.7    Bagci, H.8    Duzcan, S.E.9
  • 76
    • 65849287224 scopus 로고    scopus 로고
    • Role of polysomy 17 in transitional cell carcinoma of the bladder: Immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17
    • Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009; 17(3): 198-205.
    • (2009) Int J Surg Pathol , vol.17 , Issue.3 , pp. 198-205
    • Simonetti, S.1    Russo, R.2    Ciancia, G.3    Altieri, V.4    de Rosa, G.5    Insabato, L.6
  • 77
    • 48649083362 scopus 로고    scopus 로고
    • HER2 overexpression and amplification in urothelial carcinoma of the bladder is associ-ated with MYC coamplification in a subset of cases
    • Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associ-ated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008; 130(2): 274-281.
    • (2008) Am J Clin Pathol , vol.130 , Issue.2 , pp. 274-281
    • Hansel, D.E.1    Swain, E.2    Dreicer, R.3    Tubbs, R.R.4
  • 78
    • 67349136325 scopus 로고    scopus 로고
    • Immunohistochemical com-parison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the uri-nary tract and typical invasive urothelial carci-noma with retraction artifact
    • Sangoi AR, Higgins JP, Rouse RV, Schneider AG, McKenney JK. Immunohistochemical com-parison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the uri-nary tract and typical invasive urothelial carci-noma with retraction artifact. Mod Pathol 2009; 22(5): 660-667.
    • (2009) Mod Pathol , vol.22 , Issue.5 , pp. 660-667
    • Sangoi, A.R.1    Higgins, J.P.2    Rouse, R.V.3    Schneider, A.G.4    McKenney, J.K.5
  • 79
    • 77955079033 scopus 로고    scopus 로고
    • HER-2/AKT expression in upper urinary tract urothelial carcinoma: Prognostic implications
    • Izquierdo L, Truan D, Mengual L, Mallofré C, Alcaraz A. HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res 2010; 30(6): 2439-2445.
    • (2010) Anticancer Res , vol.30 , Issue.6 , pp. 2439-2445
    • Izquierdo, L.1    Truan, D.2    Mengual, L.3    Mallofré, C.4    Alcaraz, A.5
  • 80
    • 27144451261 scopus 로고    scopus 로고
    • Trastu-zumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: Report on six patients
    • discussion 775-778
    • Peyromaure M, Scotté F, Amsellem-Ouazana D, Vieillefond A, Oudard S, Beuzeboc P. Trastu-zumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol 2005; 48(5): 771-775; discussion 775-778.
    • (2005) Eur Urol , vol.48 , Issue.5 , pp. 771-775
    • Peyromaure, M.1    Scotté, F.2    Amsellem-Ouazana, D.3    Vieillefond, A.4    Oudard, S.5    Beuzeboc, P.6
  • 81
    • 34250218955 scopus 로고    scopus 로고
    • Trastuzumab, paclitaxel, car-boplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a mul-ticenter phase II National Cancer Institute trial
    • Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC. Trastuzumab, paclitaxel, car-boplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a mul-ticenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-2224.
    • (2007) J Clin Oncol , vol.25 , pp. 2218-2224
    • Hussain, M.H.1    Macvicar, G.R.2    Petrylak, D.P.3    Dunn, R.L.4    Vaishampayan, U.5    Lara Jr., P.N.6    Chatta, G.S.7    Nanus, D.M.8    Glode, L.M.9    Trump, D.L.10    Chen, H.11    Smith, D.C.12
  • 82
    • 33847022350 scopus 로고    scopus 로고
    • Combined treatment of bladder cancer cell lines with lapatinib and varying chemo-therapy regimens-evidence of scheduled-dependent synergy
    • McHugh LA, Kriajevska M, Mellon JK, GriYths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemo-therapy regimens-evidence of scheduled-dependent synergy. Urology 2007;69(2):390-394.
    • (2007) Urology , vol.69 , Issue.2 , pp. 390-394
    • McHugh, L.A.1    Kriajevska, M.2    Mellon, J.K.3    Griyths, T.R.4
  • 85
    • 67649579849 scopus 로고    scopus 로고
    • A single-arm, multicen-ter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    • Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F, El-Hariry IA. A single-arm, multicen-ter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115(13): 2881-2890.
    • (2009) Cancer , vol.115 , Issue.13 , pp. 2881-2890
    • Wülfing, C.1    Machiels, J.P.2    Richel, D.J.3    Grimm, M.O.4    Treiber, U.5    de Groot, M.R.6    Beuzeboc, P.7    Parikh, R.8    Pétavy, F.9    El-Hariry, I.A.10
  • 87
    • 0029741999 scopus 로고    scopus 로고
    • Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tu-mours
    • DiGiovanna MP, Carter D, Flynn SD, Stern DF. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tu-mours. Br J Cancer 1996; 74: 802-806.
    • (1996) Br J Cancer , vol.74 , pp. 802-806
    • Digiovanna, M.P.1    Carter, D.2    Flynn, S.D.3    Stern, D.F.4
  • 88
    • 33644750227 scopus 로고    scopus 로고
    • Phosphorylation of tyrosine 1248-ERBB2 measured by chemilumines-cence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
    • Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenber-ger-Castori S. Phosphorylation of tyrosine 1248-ERBB2 measured by chemilumines-cence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006; 42: 636-645.
    • (2006) Eur J Cancer , vol.42 , pp. 636-645
    • Cicenas, J.1    Urban, P.2    Kung, W.3    Vuaroqueaux, V.4    Labuhn, M.5    Wight, E.6    Eppenberger, U.7    Eppenber-ger-Castori, S.8
  • 92
    • 67649365635 scopus 로고    scopus 로고
    • Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
    • Karamouzis MV, Konstantinopoulos PA, Pa-pavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10: 709-717.
    • (2009) Lancet Oncol , vol.10 , pp. 709-717
    • Karamouzis, M.V.1    Konstantinopoulos, P.A.2    Pa-Pavassiliou, A.G.3
  • 93
    • 0034698096 scopus 로고    scopus 로고
    • Transactivation of the EGF receptor mediates IGF-1-stimulated shc phos-phorylation and ERK1/2 activation in COS-7 cells
    • Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phos-phorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000; 275(29): 22583-22589.
    • (2000) J Biol Chem , vol.275 , Issue.29 , pp. 22583-22589
    • Roudabush, F.L.1    Pierce, K.L.2    Maudsley, S.3    Khan, K.D.4    Luttrell, L.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.